Evotec Completes Acquisition of Renovis

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Hamburg, Germany and South San Francisco, CA - Evotec AG (Frankfurt
Stock Exchange: EVT) today announced that the merger has been
successfully completed and that Renovis, Inc. (traded formerly on
NASDAQ: RNVS) is a wholly owned subsidiary of Evotec as of May 5,
2008.

In exchange for each outstanding share of Renovis common stock,
Renovis stockholders receive 0.5271 American Depositary Shares, or
ADSs, of Evotec, which have been approved for listing on the NASDAQ
Global Market under the trading symbol "EVTC". The trading will be
initiated today and the ADSs will trade on a "when issued" basis
under the symbol "EVTCV" until they are eligible for normal trade
settlement, currently anticipated to be within two weeks of the
acquisition.

Each Evotec ADS represents two ordinary shares of Evotec. As a
result, Evotec is issuing an aggregate of 34,970,268 new ordinary
shares, which underly the ADSs issued to Renovis stockholders.
Current Evotec stockholders now own approximately 68.8% of the
combined company and Renovis stockholders own up to 31.2%. To ensure
that new Evotec shareholders will be able to participate in this
year's Annual General Meeting, Evotec has scheduled the meeting to be
held on August 28, 2008.

The Executive Management Team of Evotec is the Executive Management
Team of the combined company with Jörn Aldag serving as President &
Chief Executive Officer. Dr Michael Kelly, currently Senior Vice
President, Research & Development of Renovis, will join Evotec's
Executive Management Team and will be President of Evotec's site in
California. The combined company's Supervisory Board will consist of
six directors. At Evotec's upcoming Annual General Meeting, Dr Corey
Goodman, former Chief Executive Officer & President of Renovis, and
John Walker, Executive Chairman and Principal Executive Officer of
Renovis are expected to be elected as new members of Evotec's
Supervisory Board.

"The acquisition enhances Evotec's emerging clinical story. Our three
clinical candidates are now backed by a strong late stage preclinical
pipeline focusing on areas of neurological and inflammatory diseases,
and we have pro-forma cash and investments of approximately US$ 188
million (as of March 31, 2008). By combining Evotec's drug discovery
and development know-how with Renovis' medicinal chemistry and target
validation expertise, we now have world class discovery capabilities,
a strong pipeline in CNS disorders and several significant research
partnerships with leading pharmaceutical companies such as Boehringer
Ingelheim, Pfizer and Roche. By the end of 2009, we expect to have at
least 6 compounds in clinical development, 3 of which should have
proof-of-concept data to attract partners, and our cash is expected
to last through 2010," said Jörn Aldag, President & Chief Executive
Officer of Evotec.

Key highlights of Evotec now include: Three clinical programs, three
advanced preclinical programs, and partnerships

* EVT 201: a partial positive allosteric modulator (pPAM) of GABAA
receptors for the treatment of insomnia. In 2007, the compound
has shown robust effects on sleep onset and sleep maintenance in
two Phase II proof-of-concept studies in adult primary insomnia
patients and elderly primary insomniacs. The data provided
encouraging evidence of the drug's potential to address many of
the shortcomings of commercially available prescription sleep
aids. Evotec intends to partner EVT 201 in 2008.

* EVT 101: one of the few orally active and selective antagonists
of the NR2B subunit-containing NMDA receptors in clinical
development. Its selectivity may offer clinical advantages over
current Alzheimer therapies and the Company believes that there
is significant potential in a number of pain indications. EVT 101
was well tolerated in Phase I studies and recently released
initial data from Phase Ib studies has confirmed our enthusiasm
for the drug candidate's potential to enter the brain and affect
those regions of the brain that relate to the performance of
cognitive tasks and to pain. Additional data from these studies
is expected this quarter.

* EVT 302: an orally active, highly selective and reversible
inhibitor of MAO-B in development for smoking cessation with a
potential additive effect to nicotine-based therapies, and with
the potential for once per week dosing and for a superior safety
profile. Results from Phase I PET and safety and tolerability
studies were reported since the announcement of the transaction,
which laid a foundation for moving forward to Phase II
proof-of-concept trials. A Phase II craving study started in
February 2008 and a Phase II quit rate study is expected to start
in the middle of the year. The studies will read out in the third
quarter 2008 and the first half of 2009, respectively.

.Innovative preclinical pipeline
The combined company's preclinical pipeline complements Evotec's
clinical portfolio, and includes candidates expected to enter Phase I
clinical trials in 2008:

* VR1 antagonists: The lead preclinical program is a collaboration
with Pfizer Inc. in which Evotec will be eligible to receive
milestone payments of more than US$ 170 million and double-digit
royalties on worldwide net sales of products successfully
developed and commercialized. Potential products include broadly
applicable analgesics with a potentially differentiated profile
for a variety of chronic or acute pain indications as well as
urinary incontinence and asthma. Entry into human clinical trials
is expected for the first half of 2008.

* P2X7 antagonists: Products include potential novel treatments for
rheumatoid arthritis, irritable bowel syndrome, and chronic
obstructive pulmonary disease. Human clinical trials are expected
to begin in 2008. The program is unpartnered, and as such Evotec
has worldwide rights for its development.

* P2X3 antagonists: Products include potential first-in-class
treatments for inflammatory/neuropathic pain and urinary
disorders. Human clinical trials are expected to begin in the
first half of 2009. The program is unpartnered, and as such
Evotec has worldwide rights for its development.

.Partnerships

* Evotec has research partnerships with a number of pharmaceutical
and biotechnology companies, research foundations and renowned
academic institutes, including Boehringer Ingelheim, CHDI, Pfizer
and Roche.

.Advisers

* Lehman Brothers Inc. served as the financial advisor to Evotec.

* Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and
Freshfields Bruckhaus Deringer were legal counsel.

Contact: Anne Hennecke, Senior Vice President, Investor Relations &
Corporate Communications, Evotec AG, Phone: +49.(0)40.56081-286,
anne.hennecke@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about the anticipated benefits of our products, the
anticipated benefits of the merger, including future financial and
operating results, the combined company's plans, objectives,
expectations and intentions, the anticipated timing and results of
the combined company's clinical and pre-clinical programs, and other
statements that are not historical facts. We caution readers that any
forward-looking information is not a guarantee of future performance
and that actual results could differ materially from those contained
in the forward-looking information. These include risks and
uncertainties relating to: our failure to successfully integrate the
businesses; unexpected costs or liabilities resulting from the
merger; the risk that synergies from the merger may not be fully
realized or may take longer to realize than expected; disruption from
the merger making it more difficult to maintain relationships with
customers, employees or suppliers; competition and its effect on
pricing, spending, third-party relationships and revenues; the need
to develop new products and adapt to significant technological
change; implementation of strategies for improving internal growth;
use and protection of intellectual property; general worldwide
economic conditions and related uncertainties; future legislative,
regulatory, or tax changes as well as other economic, business and/or
competitive factors; and the effect of exchange rate fluctuations on
our international operations. The list of risks above is not
exhaustive. Our Registration Statement on Form F-4, as amended, filed
with the Securities and Exchange Commission in connection with the
merger, and other filings and items furnished with the Securities
and Exchange Commission, contain additional factors that could impact
our businesses and financial performance following the merger. We
expressly disclaim any obligation or undertaking to release publicly
any updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München,

Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover;